JOHN VIERLING to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications JOHN VIERLING has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.069
-
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials. Am J Gastroenterol. 2018 06; 113(6):863-871.
Score: 0.035
-
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018 May; 53(5):679-688.
Score: 0.034